Sunday, August 11, 2013

Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer

  • Grandis JR, Sok JC: Signaling through the epidermal growth factor receptor during the development of malignancy.

    Pharmacol Ther 2004, 102:37-46. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Holbro T, Civenni G, Hynes NE: The ErbB receptors and their role in cancer progression.

    Exp Cell Res 2003, 284:99-110. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Sharma SV, Bell DW, Settleman J, Haber DA: Epidermal growth factor receptor mutations in lung cancer.

    Nat Rev Cancer 2007, 7:169-181. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Tabernero J, Van CE, az-Rubio E, Cervantes A, Humblet Y, Andre T, Van Laethem JL, Soulie P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de GA: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.

    J Clin Oncol 2007, 25:5225-5232. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Peeters M, Balfour J, Arnold D: Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer.

    Aliment Pharmacol Ther 2008, 28:269-281. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Sharma PS, Sharma R, Tyagi T: Receptor tyrosine kinase inhibitors as potent weapons in war against cancers.

    Curr Pharm Des 2009, 15:758-776. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Dziadziuszko R, Hirsch FR, Varella-Garcia M, Bunn PA Jr: Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?

    Clin Cancer Res 2006, 12:4409s-4415s. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A: Clinical relevance of EGFR-and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.

    Cancer Treat Rev 2009, 35:262-271. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA Jr: Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

    Ann Oncol 2007, 18:752-760. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di NF, Gambacorta M, Siena S, Bardelli A: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

    Lancet Oncol 2005, 6:279-286. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

    N Engl J Med 2004, 350:2129-2139. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Moroni M, Sartore-Bianchi A, Veronese S, Siena S: EGFR FISH in colorectal cancer: what is the current reality?

    Lancet Oncol 2008, 9:402-403. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di TL, Holmes AJ, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A, Janne PA: Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.

    Br J Cancer 2008, 99:83-89. PubMed?Abstract | Publisher?Full?Text | PubMed?Central?Full?Text OpenURL

  • Neal JW: Histology matters: individualizing treatment in non-small cell lung cancer.

    Oncologist 2010, 15:3-5. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Tanner M, Gancberg D, Di LA, Larsimont D, Rouas G, Piccart MJ, Isola J: Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.

    Am J Pathol 2000, 157:1467-1472. PubMed?Abstract | PubMed?Central?Full?Text OpenURL

  • Smouse JH, Cibas ES, Janne PA, Joshi VA, Zou KH, Lindeman NI: EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer.

    Cancer Cytopathol 2009, 117:67-72. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Goldstein NS, Armin M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system.

    Cancer 2001, 92:1331-1346. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Daniele L, Macri L, Schena M, Dongiovanni D, Bonello L, Armando E, Ciuffreda L, Bertetto O, Bussolati G, Sapino A: Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.

    Mol Cancer Ther 2007, 6:1223-1229. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Vocaturo A, Novelli F, Benevolo M, Piperno G, Marandino F, Cianciulli AM, Merola R, Donnorso RP, Sperduti I, Buglioni S, Mottolese M: Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era.

    Oncologist 2006, 11:878-886. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Sholl LM, John IA, Chou YP, Wu MT, Goan YG, Su L, Huang YT, Christiani DC, Chirieac LR: Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma.

    Mod Pathol 2007, 20:1028-1035. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Hoag JB, Azizi A, Doherty TJ, Lu J, Willis RE, Lund ME: Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review.

    J Exp Clin Cancer Res 2009, 28:113. PubMed?Abstract | BioMed?Central?Full?Text | PubMed?Central?Full?Text OpenURL

  • Rossi G, Pelosi G, Graziano P, Barbareschi M, Papotti M: A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments.

    Int J Surg Pathol 2009, 17:206-218. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Spiro SG, Porter JC: Lung cancer--where are we today? Current advances in staging and nonsurgical treatment.

    Am J Respir Crit Care Med 2002, 166:1166-1196. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Ciardiello F, Tortora G: EGFR antagonists in cancer treatment.

    N Engl J Med 2008, 358:1160-1174. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

    Lancet 2008, 372:1809-1818. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Crino L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, Ford HE, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Duffield EL, Armour AA, Speake G, Cullen M: Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.

    J Clin Oncol 2008, 26:4253-4260. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Morinaga R, Okamoto I, Fujita Y, Arao T, Sekijima M, Nishio K, Ito H, Fukuoka M, Kadota J, Nakagawa K: Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer.

    Cancer Sci 2008, 99:2455-2460. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Horiike A, Kimura H, Nishio K, Ohyanagi F, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T, Nishio M: Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer.

    Chest 2007, 131:1628-1634. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Gupta R, Dastane AM, McKenna R, Marchevsky AM: The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis.

    Hum Pathol 2009, 40:356-365. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, Siena S: Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.

    J Clin Oncol 2007, 25:3238-3245. PubMed?Abstract | Publisher?Full?Text OpenURL

  • Campanella C, Mottolese M, Cianciulli A, Torsello A, Merola R, Sperduti I, Melucci E, Conti S, Diodoro MG, Zeuli M, Paoletti G, Cognetti F, Garufi C: Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab.

    J Transl Med 2010, 8:36. PubMed?Abstract | BioMed?Central?Full?Text | PubMed?Central?Full?Text OpenURL

    • Source: http://www.jeccr.com/content/29/1/125

    acm awards 2012 january jones ncaa final game reba mcentire acm awards global payments eli young band

    Posted by at

    No comments:

    Post a Comment

    Subscribe to: Post Comments (Atom)